A carregar...
Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
Although crizotinib has demonstrated promising efficacy and acceptable toxicity in patients with advanced non‐small cell lung cancer (NSCLC), the available evidence in Chinese populations is currently limited. This study compared the progression‐free survival (PFS) of Chinese patients with anaplasti...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4924358/ https://ncbi.nlm.nih.gov/pubmed/26880708 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.659 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|